MyMedR

Fulltext Anti-hepatitis A seroprevalence among chronic viral hepatitis patients in Kelantan, Malaysia

Ahmad F, Hamzah NA, Mustaffa N, Gan SH

World J Gastroenterol, 2011 Sep 28;17(36):4130-4.

PMID: 22039329 DOI: 10.3748/wjg.v17.i36.4130

To determine the seroprevalence of anti-hepatitis A virus (HAV) antibodies in patients with chronic liver disease (CLD) and to justify the need for hepatitis A vaccination.

Matched MeSH terms: Hepatitis A Antibodies/blood*; Hepatitis A Antibodies/immunology

CYP3A4*18 polymorphisms and anti-hepatitis A virus seroprevalence

Ahmad F, Che Hamzah NA, Mustaffa N, Hua GS

Hepatogastroenterology, 2011 07 15;58(110-111):1725-9.

PMID: 21940338 DOI: 10.5754/hge11107

BACKGROUND/AIMS: CYP3A4 is the major cytochrome in humans which shows reduced activity in chronic liver disease as well as in hepatic cirrhosis. The detection of this polymorphism may give an indication on the prognosis of patients having chronic viral hepatitis with superimposed hepatitis A infection. The aim of this study is to correlate the seroprevalence of anti-HAV antibodies in chronic liver disease patients having CYP3A4*18 polymorphisms.

METHODOLOGY: This is a prospective study where patients (n=119) blood was tested for anti-HAVIgG and CYP3A4*18 polymorphism.

RESULTS: The overall anti-HAV seroprevalence was 88.2%. The etiology of CLD was hepatitis B in 96 patients (80.7%) and hepatitis C in 23 patients (19.3%). There was a significant increase in the age of the prevalence of this disease after 30 years of age (p=0.008). CYP3A4*18 polymorphism was detected in 3 (2.5%) of the patients with chronic liver disease. However, there was no significant association between CP3A4*18 mutation and anti-HAV serology.

CONCLUSIONS: Age was the most important factor in determining anti-HAV positivity. It is concluded that CYP3A4*18 genetic polymorphism does not play a main role in influencing the seroprevalence of anti-hepatitis A among chronic viral hepatitis B and C liver disease patients.

Matched MeSH terms: Hepatitis A Antibodies/blood*

Fulltext Prevalence of hepatitis A virus infection in normal individuals and hospital patients in Kuala Lumpur

Ton SH, Thiruselvam A, Lopez CG, Noriah R

Med J Malaysia, 1983 Dec;38(4):279-81.

PMID: 6100990

110 normal, healthy adults were tested for antibody to hepatitis A (anti-HA) type IgG and 86 (78.2%) were found to be positive. An age-specific prevalence wasfound to be lowest in the lower agegroup and highest in the higher age-group. Out of 24 IgG positive individuals, only one was found to have type IgM. No significant difference in the incidence ofanti-HA type IgG was found between 42 patients in the Urology Unit, General Hospital, Kuala Lumpur and normal individuals (P > 0.1). 15 patients diagnosed as viral hepatitis were investigated for HA V IgG and IgM antibodies. 13 (86.7%) were positive for type IgG. Of this, only five (33%) were positive for the type IgM, suggesting that HA V is the cause of acute viral hepatitis in 33% of cases admitted to hospital as viral hepatitis.

Matched MeSH terms: Hepatitis A Antibodies

A seroepidemiologic study of hepatitis A in Malaysia

Tan DS, Fang R, Collett D, Ooi BG

Southeast Asian J Trop Med Public Health, 1986 Jun;17(2):201-4.

PMID: 3538434

Sera from 494 non-icteric patients admitted with illnesses other than overt hepatitis into the various hospitals in rural and urban Malaysia were tested for IgG antibody to hepatitis A virus. The overall antibody prevalence rate was 67.0% with rates increasing steadily from childhood 10 years old and under (39.4%) to middle-age and above (96.0%). No significant differences were noted between males (68.4%) and females (65.3%). The highest rate was in the Indians (80.6%), the lowest in the Chinese (55.9%) with Malays occupying intermediate position (70.3%). The rate in the rural patients (74.7%) was higher than that in the urban patients (65.5%) especially in the 21 to 40 year age-group where the rural patients had a rate of 96.7% compared with that in urban patients (61.1%). A comparison of antibody prevalence rates in different countries was made.

Matched MeSH terms: Hepatitis A Antibodies

Hepatitis A vaccines

Shahidah KN

Med J Malaysia, 2005 Jul;60 Suppl B:112-5.

PMID: 16108190

Hepatitis A, an acute usually self limiting infection of the liver is one of the most common vaccine-preventable infectious disease in the world. Effective vaccines which provide long term immunity against hepatitis A have been available since 1992. They are of known good quality, well tolerated with no serious adverse events and have been successfully used to protect different populations from infection as well as interrupt outbreak in closed communities. Mathematical models estimate the long term persistence of antiHAV antibodies to be more than 25 years. Vaccination efforts should be supplemented by health education and improved sanitation. Planning for large scale immunization programmes against hepatitis A should take into consideration epidemiological and cost benefit studies.

Matched MeSH terms: Hepatitis A Antibodies

Wild Malaysian cynomolgus monkeys are exposed to hepatitis A virus

Burke DS, Heisey GB

Am J Trop Med Hyg, 1984 Sep;33(5):940-4.

PMID: 6486304

Serum samples were obtained within 3 days of capture from 106 cynomolgus monkeys (Macaca fascicularis) in peninsular Malaysia. Fifty-two monkeys were trapped on the fringes of palm oil estates and 54 in dense primary jungle. Sera were tested for antibodies to hepatitis A virus (HAV) with a commercial radioimmunoassay. Twenty-four animals had detectable serum anti-HAV activity (6 of 52 from palm oil estate sites and 18 of 54 from primary jungle sites). Among monkeys at both sites, antibody prevalence was strongly correlated with animal weight: overall only four of 69 monkeys (6%) weighing less than 2.0 kg had serum anti-HAV antibodies, while 14 of 29 (48%) weighing 2.0 to 3.9 kg, and 6 of 8 (75%) weighing 4.0 kg or more, had serum anti-HAV antibodies. These data suggest that wild cynomolgus monkeys in Malaysian jungles become infected with HAV or an HAV-like virus at a rate comparable to that of humans in the same region, and raise the possibility of a sylvatic cycle for HAV.

Matched MeSH terms: Hepatitis A Antibodies

Displaying all 6 publications